The field of antibody engineering, while having delivered groundbreaking therapeutics, continues to seek technological innovations. Genetic code expansion (GCE) represents a cutting-edge approach that utilizes engineered orthogonal aminoacyl-tRNA synthetase (aaRS)/tRNA pairs to site-specifically incorporate non-canonical amino acids (ncAAs) into proteins. This provides a novel toolkit for expanding the chemical and functional diversity of antibodies. Serving as a trusted partner in ncAA-incorporated antibody engineering, our company offers a seamless, one-stop solution from initial pair identification to complex in vivo applications that utilize our proprietary GCEngine platform.
Traditional antibody engineering often relies on stochastic conjugation methods, which frequently result in heterogeneous products with unpredictable pharmacokinetic profiles and diminished efficacy. GCE technology addresses this by repurposing stop codons (such as the amber stop codon, UAG) to introduce ncAAs bearing unique chemical handles (e.g., azides, alkynes) at predetermined sites within an antibody. This site-specific precision offers a more controlled strategy for developing homogeneous antibody-drug conjugates (ADCs), bispecific antibodies, or labeled probes. Currently, research into GCE-based antibody engineering is rapidly evolving, demonstrating its significant potential for future drug discovery.
Fig.1 GCE enables the site-specific conjugation of radioisotopes to antibodies. (Koehler, C., et al., 2023)
Leveraging a high-throughput platform for orthogonal aaRS/tRNA pairs identification, we offer full-spectrum collaborative research and development services for the design, validation, and application of ncAA-incorporated antibodies. Our systematic platform supports projects from initial pair screening tailored to your target ncAA and antibody sequence, through to extensive in vitro and in vivo validation, aiming to produce functional, stable, and pharmacologically relevant engineered molecules.
Leveraging the core capabilities described above, our GCEngine platform enables several key application-driven services:
Combining expertise in orthogonal biology with robust preclinical capabilities, we partner with clients to deliver innovative solutions from concept to validation. Our integrated solution is designed to help systematically advance projects and tackle development challenges, providing the critical tools needed to create differentiated antibody-based therapeutics. For detailed project consultations and to explore how our GCEngine platform can advance your antibody engineering programs, please contact our scientific team today.
All our services are exclusively intended for preclinical research purposes. They are not intended for diagnostic, therapeutic, or patient management applications.
A specialized platform advancing genetic code expansion through orthogonal tRNA/aaRS technologies, enabling precise ncAA incorporation for biotherapeutic development, synthetic biology, and diagnostics.